Ilex-Millennium joint venture responds to FDA letter

Millennium & Ilex Partners, a joint venture between ILXO and MLNM, responded to a June complete response letter from the FDA regarding its 1999 BLA for Campath alemtuzumab, a monoclonal antibody to tr...